Durvalumab boosts progression-free survival in NSCLC

Gourd Elizabeth

首页> 外文期刊>The lancet oncology >Durvalumab boosts progression-free survival in NSCLC

【24h】

Durvalumab boosts progression-free survival in NSCLC

机译：Durvalumab在NSCLC中提高了无进展的生存

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《The lancet oncology》 |2018年第1期|共1页
作者
Gourd Elizabeth;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. Durvalumab boosts progression-free survival in NSCLC [J] . Gourd Elizabeth The lancet oncology . 2018,第1期

机译：Durvalumab在NSCLC中提高了无进展的生存
2. Progression-Free Survival and Overall Survival Beyond 5 Years of NSCLC Patients With Synchronous Oligometastases Treated in a Prospective Phase II Trial (NCT 01282450) [J] . Dirk De Ruysscher, Rinus Wanders, Lizza E. Hendriks, Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer . 2018,第12期

机译：在预期期II试验中治疗的同步寡聚蛋白的NSCLC患者超过5年的无进展生存和整体存活率（NCT 01282450）
3. The Impact of Staging by Positron-Emission Tomography on Overall Survival and Progression-Free Survival in Patients With Locally?Advanced NSCLC [J] . Everett E. Vokes, Ramaswamy Govindan, Neill Iscoe, Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer . 2018,第8期

机译：正电子排放断层扫描对本地患者的整体存活和无进展生存的影响？高级NSCLC
4. Development and validation of a radiomics nomogram for progression-free survival prediction in stage IV EGFR-mutant non-small cell lung cancer [C] . Jiangdian Song, Yali Zang, Weimin Li, Conference on Computer-Aided Diagnosis . 2017

机译：放射组学诺模图的开发和验证，用于IV期EGFR突变非小细胞肺癌的无进展生存期预测
5. Statistical Models to Capture the Association Between Progression-Free and Overall Survival in Oncology Trials [D] . Weber, Enya Maria. 2020

机译：统计模型捕获肿瘤学试验无进展和整体生存之间的关联
6. Chinese Medicine Combined With EGFR-TKIs Prolongs Progression-Free Survival and Overall Survival of Non-small Cell Lung Cancer (NSCLC) Patients Harboring EGFR Mutations Compared With the Use of TKIs Alone [O] . Yujia Wang, Guoyu Wu, Ru Li, 2021

机译：中医结合EGFR-TKIS延长了无小细胞肺癌（NSCLC）患有EGFR突变的非小细胞肺癌（NSCLC）患者的进展生存和整体存活率而单独使用TKIS
7. Differences in treatment effect size between progression-free survival and overall survival in anti-PD-1/PD-L1 inhibitors-based trials in advanced NSCLC: a systematic review and meta-analysis [O] . Zhirui Zhou, Shengxiang Ren, Lingxiao Chen, 2021

机译：在先进的NSCLC中，无PD-1 / PD-L1抑制剂的无进展存活和整体存活之间的治疗效果大小的差异：系统评价和荟萃分析

Durvalumab boosts progression-free survival in NSCLC

著录项

相似文献

相关主题

期刊订阅